Coya Therapeutics, Inc. (COYA) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-01-26

Key Insights

Arun Swaminathan, the CEO of Coya Therapeutics, Inc. (COYA), has acquired 293,983 stock options with an exercise price of $4.73, vesting over the next 36 months.
The option grant is likely part of Swaminathan's compensation package and aligns his interests with shareholders through equity ownership.
The options will fully vest upon a change in control of the company, providing an incentive for Swaminathan to act in the best interests of shareholders during a potential acquisition or merger.

Want the newest filings?

This analysis covers the filing from 2026-01-26. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-01-26

Insider Howard Berman, the Executive Chairman, acquired 15,257 stock options in Coya Therapeutics, Inc. on January 22, 2026 at an exercise price of $4.73.
The options will vest in monthly installments over the next 36 months, with full vesting upon a change in control of the company.
This insider purchase signals Berman's confidence in the company's prospects and long-term growth potential.

Filed: 2026-01-26

Fred Grossman, the Chief Medical Officer of Coya Therapeutics, Inc., has acquired 140,041 stock options with an exercise price of $4.73 and a 10-year expiration date.
The options will vest in monthly installments over the next 36 months, with accelerated vesting upon a change in control of the company.
This insider buying activity suggests that Grossman is confident in the company's future prospects and aligns his interests with those of shareholders.

Filed: 2026-01-26

David Snyder, the Chief Financial Officer of Coya Therapeutics, Inc. (COYA), has been granted 140,041 stock options with an exercise price of $4.73 and a vesting period of 36 months.
The stock options will become fully vested and exercisable upon a change in control of the company, indicating the potential importance of this transaction for Snyder and the company.
This filing suggests that Snyder is aligning his interests with the company's long-term success, as the options will only be valuable if the stock price increases over time.

Filed: 2026-01-06

The reporting person, Lee Ann, has been granted a stock option to acquire 10,000 shares of Coya Therapeutics, Inc. common stock at an exercise price of $5.65 per share. The option vests in full on the first anniversary of the grant date.
This filing indicates insider buying activity, which can be a positive signal for investors about management's confidence in the company's prospects.
The significant number of shares (10,000) and the relatively low exercise price of the option suggest that the reporting person may be taking a long-term, strategic position in the company.

Filed: 2026-01-06

Wilbur L. Ross Jr., a director of Coya Therapeutics, Inc., acquired 10,000 stock options with an exercise price of $5.65 on January 2, 2026. This suggests the director is expressing confidence in the company's future performance.
The stock options have a 10-year term and vest fully on the first anniversary of the grant date, indicating the director's long-term commitment to the company.
Insider buying, such as this transaction by a director, can be a positive signal to investors about the company's prospects and the director's belief in the company's future growth.

Filed: 2026-01-06

Dieter Weinand, a director of Coya Therapeutics, Inc. (COYA), acquired 10,000 stock options on January 2, 2026 with an exercise price of $5.65 per share and a 10-year term.
The options will vest 100% on the first anniversary of the grant date, indicating Weinand's long-term commitment to the company.
This insider purchase suggests Weinand's confidence in Coya Therapeutics' future prospects and could signal positive sentiment among the company's leadership.

Filed: 2026-01-06

The reporting person, Dov A. Goldstein, M.D., a director of Coya Therapeutics, Inc., acquired 10,000 stock options on January 2, 2026 with an exercise price of $5.65 per share and a vesting period of one year.
The acquisition of these stock options suggests Goldstein's continued confidence in the company's long-term prospects and aligns his interests with those of other shareholders.
The timing of the transaction, which occurred shortly after the start of the new year, may indicate Goldstein's belief in the company's potential for growth and development in the coming year.

Filed: 2026-01-06

Anabella Villalobos, a director of Coya Therapeutics, Inc., acquired 10,000 stock options with an exercise price of $5.65 on January 2, 2026, indicating insider confidence in the company's prospects.
The options will vest fully on the first anniversary of the grant date, aligning Villalobos's incentives with long-term shareholder value creation.
This insider transaction suggests the director believes Coya Therapeutics' stock is undervalued and has potential for future growth.

Other reports for Coya Therapeutics, Inc.

Current Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.